Which pain intensity scale from the Brief Pain Inventory correlates most highly with functional interference scores in patients experiencing taxane-induced arthralgia and myalgia?
- PMID: 26868953
- DOI: 10.1007/s00520-016-3106-5
Which pain intensity scale from the Brief Pain Inventory correlates most highly with functional interference scores in patients experiencing taxane-induced arthralgia and myalgia?
Abstract
Purpose: The purpose of this study was to assess which pain intensity dimension scale (worst, least, average, or current pain) from the Brief Pain Inventory (BPI) correlates most highly with functional interference scores in patients experiencing taxane-induced arthralgia and myalgia.
Methods: Breast cancer patients scheduled to receive docetaxel, paclitaxel, or albumin-bound paclitaxel (nab-paclitaxel) were enrolled in the study. Patients completed an initial baseline questionnaire and subsequently filled out a diary based on the BPI on days 1-7, 14, and 21 for three consecutive treatment cycles. Pain scores for worst, least, average, and current pain intensity dimensions as well as pain interference scores were recorded in the diaries and questionnaires using the BPI. Worst, least, average, and current pain scores were correlated with functional pain interference scores using Spearman's rank correlation coefficients. A general linear mixed model of each functional interference measure was performed over time for cycles 1-3 with each pain intensity dimension scale.
Results: Among worst, average, least, and current joint pain dimensions, average joint pain scores correlated best with all BPI interference responses while average muscle pain scores correlated best with all BPI interference responses except for sleeping probability and normal work.
Conclusion: We recommend the BPI scale measuring average pain for future studies evaluating pain scores in patients experiencing taxane-induced arthralgia and myalgia.
Keywords: Arthralgia; Brief pain inventory; Myalgia; Pain score; Taxane.
Similar articles
-
A prospective study of docetaxel-associated pain syndrome.Support Care Cancer. 2018 Jan;26(1):203-211. doi: 10.1007/s00520-017-3836-z. Epub 2017 Jul 22. Support Care Cancer. 2018. PMID: 28733699
-
Taxane-induced arthralgia and myalgia: A literature review.J Oncol Pharm Pract. 2017 Jan;23(1):56-67. doi: 10.1177/1078155215627502. Epub 2016 Jun 23. J Oncol Pharm Pract. 2017. PMID: 26811404 Review.
-
Taxane acute pain syndrome (TAPS) in patients receiving chemotherapy for breast or prostate cancer: a prospective multi-center study.Support Care Cancer. 2018 Sep;26(9):3073-3081. doi: 10.1007/s00520-018-4161-x. Epub 2018 Mar 21. Support Care Cancer. 2018. PMID: 29564623
-
Worst, average or current pain in the Brief Pain Inventory: which should be used to calculate the response to palliative radiotherapy in patients with bone metastases?Clin Oncol (R Coll Radiol). 2007 Sep;19(7):523-7. doi: 10.1016/j.clon.2007.04.007. Epub 2007 Jun 12. Clin Oncol (R Coll Radiol). 2007. PMID: 17566723
-
Pain assessment: global use of the Brief Pain Inventory.Ann Acad Med Singap. 1994 Mar;23(2):129-38. Ann Acad Med Singap. 1994. PMID: 8080219 Review.
Cited by
-
Pain descriptors of taxane acute pain syndrome (TAPS) in breast cancer patients-a prospective clinical study.Support Care Cancer. 2020 Feb;28(2):589-598. doi: 10.1007/s00520-019-04845-7. Epub 2019 May 17. Support Care Cancer. 2020. PMID: 31098795
-
Patient-Reported Outcomes and Opioid Use by Outpatient Cancer Patients.J Pain. 2018 Mar;19(3):278-290. doi: 10.1016/j.jpain.2017.11.001. Epub 2017 Nov 14. J Pain. 2018. PMID: 29154919 Free PMC article.
-
Chemotherapy-Induced Neuropathy in Cancer Survivors.J Pain Symptom Manage. 2017 Aug;54(2):204-218.e2. doi: 10.1016/j.jpainsymman.2016.12.342. Epub 2017 Jan 4. J Pain Symptom Manage. 2017. PMID: 28063866 Free PMC article.
-
A prospective study of docetaxel-associated pain syndrome.Support Care Cancer. 2018 Jan;26(1):203-211. doi: 10.1007/s00520-017-3836-z. Epub 2017 Jul 22. Support Care Cancer. 2018. PMID: 28733699
-
A proof-of-concept trial of protein kinase C iota inhibition with auranofin for the paclitaxel-induced acute pain syndrome.Support Care Cancer. 2017 Mar;25(3):833-838. doi: 10.1007/s00520-016-3467-9. Epub 2016 Nov 12. Support Care Cancer. 2017. PMID: 27838777 Free PMC article. Clinical Trial.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources